Use of bradykinin-B2 receptor antagonists for treating osteoarthrosis

Details for Australian Patent Application No. 2004210396 (hide)

Owner Aventis Pharma Deutschland GmbH

Inventors Michaelis, Martin; Rudolphi, Karl

Agent Watermark

Pub. Number AU-A-2004210396

PCT Pub. Number WO2004/069266

Priority 103 04 994.0 07.02.03 DE

Filing date 23 January 2004

Wipo publication date 19 August 2004

International Classifications

A61K 038/04 Medicinal preparations containing peptides - Peptides having up to 20 amino acids in a fully defined sequence

A61P 019/00 Drugs for skeletal disorders

Event Publications

25 August 2005 PCT application entered the National Phase

  PCT publication WO2004/069266 Priority application(s): WO2004/069266

22 December 2005 Assignment before Grant

  Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH

19 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004210399-Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones

2004210394-Edible emulsion spread